诺和诺德扩产:减重市场战局从注射转向口服 巨头角力进入下半场

21世纪经济报道
Mar 03

面对专利悬崖的倒计时与后来者虎视眈眈的追赶,丹麦制药巨头诺和诺德正在打一场前所未有的“保卫战”。  3月2日,诺和诺德宣布了一项重大战略部署:投资4.32亿欧元(约合32亿丹麦克朗)扩建其位于爱尔兰阿斯隆的生产基地,旨在显著提升其口服GLP-1疗法的生产能力。公开信息显示,整个项目占地 45 英亩(18 公顷),将创造多达 500 个建筑工作岗位。该建设项目已经启动,并将于 2027 年底至 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10